Wall Street brokerages predict that Endo International PLC (NASDAQ:ENDP) will report $0.74 earnings per share for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Endo International PLC’s earnings. The highest EPS estimate is $0.81 and the lowest is $0.65. Endo International PLC reported earnings per share of $0.86 during the same quarter last year, which suggests a negative year-over-year growth rate of 14%. The business is expected to issue its next quarterly earnings results before the market opens on Tuesday, August 8th.

On average, analysts expect that Endo International PLC will report full year earnings of $3.47 per share for the current fiscal year, with EPS estimates ranging from $3.30 to $3.63. For the next year, analysts anticipate that the company will report earnings of $3.26 per share, with EPS estimates ranging from $2.39 to $4.00. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that follow Endo International PLC.

Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Tuesday, May 9th. The company reported $1.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.10 by $0.13. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the company earned $1.08 earnings per share. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year.

A number of equities research analysts have issued reports on the stock. Canaccord Genuity set a $14.00 price target on shares of Endo International PLC and gave the company a “hold” rating in a report on Monday, May 1st. Guggenheim assumed coverage on shares of Endo International PLC in a report on Saturday, June 17th. They set a “hold” rating and a $12.00 price target for the company. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Endo International PLC in a report on Thursday, June 8th. Deutsche Bank AG decreased their price target on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, July 7th. Finally, Vetr upgraded shares of Endo International PLC from a “hold” rating to a “buy” rating and set a $11.34 price target for the company in a report on Tuesday, May 9th. Three analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have issued a buy rating to the company. Endo International PLC has a consensus rating of “Hold” and an average target price of $17.33.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/08/08/zacks-brokerages-expect-endo-international-plc-nasdaqendp-to-announce-0-74-earnings-per-share.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Point View Wealth Management Inc. raised its stake in Endo International PLC by 16.6% in the second quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after buying an additional 1,900 shares during the last quarter. Blair William & Co. IL purchased a new stake in Endo International PLC during the second quarter valued at $126,000. Gamco Investors INC. ET AL raised its stake in Endo International PLC by 5.6% in the second quarter. Gamco Investors INC. ET AL now owns 62,700 shares of the company’s stock valued at $700,000 after buying an additional 3,300 shares during the last quarter. Comerica Bank raised its stake in Endo International PLC by 1.2% in the second quarter. Comerica Bank now owns 155,786 shares of the company’s stock valued at $1,818,000 after buying an additional 1,905 shares during the last quarter. Finally, Alps Advisors Inc. raised its stake in Endo International PLC by 12.2% in the second quarter. Alps Advisors Inc. now owns 229,138 shares of the company’s stock valued at $2,559,000 after buying an additional 24,983 shares during the last quarter. 93.00% of the stock is owned by hedge funds and other institutional investors.

Shares of Endo International PLC (NASDAQ ENDP) opened at 9.31 on Tuesday. The company’s market capitalization is $2.08 billion. The company has a 50-day moving average price of $11.45 and a 200 day moving average price of $11.76. Endo International PLC has a one year low of $9.21 and a one year high of $24.93.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get a free copy of the Zacks research report on Endo International PLC (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.